Spark Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Philadelphia PA United States (2013)
Status: Acquired by Roche (2019)

Organization Overview

First Clinical Trial
2013
NCT00516477
First Marketed Drug
2017
voretigene neparvovec (Luxturna)
First NDA Approval
2017
voretigene neparvovec (Luxturna)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Spark Biomedical, Inc. | Spark Therapeutics